Show simple item record

dc.contributor.authorBremner, William J.en_US
dc.contributor.authorAmory, John K.en_US
dc.contributor.authorHerbst, Karen L.en_US
dc.contributor.authorAnawalt, Bradley D.en_US
dc.date.accessioned2008-10-17T20:42:04Z
dc.date.available2008-10-17T20:42:04Z
dc.date.issued2002-07en_US
dc.identifier.citationJ Clin Endocrinol Metab. 2002 Jul;87(7):3215-20en_US
dc.identifier.urihttp://hdl.handle.net/1773/4394
dc.description.abstractAcyline is a novel GnRH antagonist found in animal studies to be a potent suppressor of circulating gonadotropin and testosterone (T) levels. We conducted the first study of acyline administration to humans. Eight healthy, eugonadal young men were administered a series of acyline injections (0, 2.5, 7.5, 25, and 75 microg/kg), each injection separated by at least 10 d. Serum FSH, LH, and T levels were measured for 7 d after injections. Acyline suppressed FSH, LH, and T levels in a dose-dependent fashion. Maximal suppression occurred after injection of 75 microg/kg acyline, which suppressed FSH to 46.9 +/- 2.5%, LH to 12.4 +/- 2.2%, and T to 13.4 +/- 1.4% of baseline levels, maintaining suppression for over 48 h. Serum acyline levels peaked at 1 h at 18.9 +/- 0.9 ng/ml, remained significantly elevated above background 7 d after injection, and returned to background levels by 14-17 d after injection. Side-effects at the site of injection were limited to infrequent blush and pruritus that resolved within 90 min of injection. Higher doses of acyline might be effective as depot injections for long-lasting gonadotropin suppression in hormone-dependent diseases and for use in male hormonal contraception regimens.en_US
dc.language.isoen_USen_US
dc.publisherEndocrine Societyen_US
dc.subjectmale contraceptionen_US
dc.subjectandrologyen_US
dc.subject5-alpha reductase inhibitorsen_US
dc.subjecttestosteroneen_US
dc.subjectgonadotropinsen_US
dc.subject.meshSafetyen_US
dc.subject.meshResearch Support, U.S. Gov't, P.H.S.en_US
dc.subject.meshTestosterone, blooden_US
dc.subject.meshSkin, drug effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshAdulten_US
dc.subject.meshOligopeptides, adverse effects, blood, pharmacologyen_US
dc.subject.meshPruritus, chemically induceden_US
dc.subject.meshMaleen_US
dc.subject.meshGonadorelin, antagonists & inhibitorsen_US
dc.subject.meshGonadotropins, blooden_US
dc.titleAcyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonisten_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record